GlaxoSmithKline (GSK) announced Friday it has received approval from the US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research expanding the indication for FLUARIX® QUADRIVALENT (Influenza Vaccine) to include use in persons 6 months and older. Prior to this, the vaccine was only approved for active immunization against influenza A subtype viruses and type B viruses, in persons 3 years of age and older.
“The flu vaccine is the one vaccine that people of almost all ages – from 6-month-old infants to older adults – should receive annually,” said Patrick Desbiens, Senior Vice President, US Vaccines. “The expanded indication for FLUARIX®QUADRIVALENT in the US builds upon GSK’s commitment to being a reliable supplier and partner to healthcare providers and their patients. We can now offer two flu vaccines that enable providers to use the same vaccine dose to help protect all recommended persons aged 6 months and older against this potentially serious illness.”
With this approval, providers will be able to use the same dose of FLUARIX® QUADRIVALENT (15 ug of hemagglutinin per virus strain in 0.5 mL) to cover all eligible persons from 6 months of age and up.
The supplemental Biologics License Application was based on a Phase III pivotal study of the efficacy of FLUARIX®QUADRIVALENT in children 6 months through 35 months of age and on two supportive studies.
FLUARIX® QUADRIVALENT was first approved in 2012 in the US for the prevention of influenza disease in people 3 years of age and older.
- CDC: Vaccine effectiveness against the H3 viruses will probably be in the 30 percent range
- South Korea: Citrobacter freundii linked to deaths of infants at Seoul hospital
- Rabies survivor: Milwaukee protocol saves Brazilian teen
- H7N9 avian flu fatality reported in Xinjiang
- Pets: Raw meat diets pose a risk to both animal and human health
- Australia: Widespread hepatitis A local transmission among Victoria MSM reported
- Flu widespread in the US: CDC update scheduled Friday
- Ukraine: 12 kids admitted to Kiev hospital with measles since beginning of year